United States Cancer Diagnostics Market 2025 | Industry Developments, Future Growth, Share & Industry Insights | GE HealthCare, Illumina, Inc., Bio-Rad Laboratories, Hologic Inc

The Cancer Diagnostics Market reached US$ 21.71 billion in 2024 and is expected to reach US$ 42.64 billion by 2033, growing at a CAGR of 8.7% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Cancer Diagnostic Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/cancer-diagnostic-market?sg

Key Players: F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, GE HealthCare, Illumina, Inc., Bio-Rad Laboratories, Inc., Hologic, Inc., Koninklijke Philips N.V., BD, and QIAGEN.

United States - Industry Developments:

✅ Exact Sciences Launches CancerguardTM
On September 10, 2025, Exact Sciences introduced CancerguardTM, a multi-cancer early detection blood test analyzing multiple biomarker classes, enhancing early cancer detection.

✅ BillionToOne Files for U.S. IPO
On October 7, 2025, molecular diagnostics company BillionToOne filed for an initial public offering (IPO) in the United States, aiming to capitalize on renewed investor interest in IPOs after a period of slowdown earlier in the year due to trade-policy concerns.

✅ Sonic Healthcare Acquires Cairo Diagnostics
On August 21, 2025, Sonic Healthcare USA, Inc. announced the acquisition of Cairo Diagnostics LLC to expand its national hematology oncology testing capabilities.

Japan - Industry Developments:

✅ GE HealthCare and Lantheus Announce Licensing Agreement
On September 24, 2025, GE HealthCare and Lantheus announced an exclusive licensing agreement for the development and commercialization of PYLARIFY® in Japan for prostate cancer diagnostics.

✅ AmoyDx® Pan Lung Cancer PCR Panel Approved
On September 19, 2025, AmoyDx® Pan Lung Cancer PCR Panel was approved in Japan as the primary companion diagnostic for IBTROZI® (Taletrectinib adipate).

✅ Illumina's Cancer Genomic Profiling Test Receives Approval
On May 26, 2025, Illumina's TruSightTM Oncology Comprehensive for cancer genomic profiling received regulatory approval in Japan, expanding access to precision oncology options for patients.

South Korea - Industry Developments:

✅ Noul Secures FDA Registration for Cervical Cancer Diagnostic
On September 23, 2025, Noul's miLabTM Platform received FDA registration for its cervical cancer diagnostic, fully automating the microscopic diagnostic process.

✅ Lunit and Agilent Technologies Announce Collaboration
On September 22, 2025, Lunit and Agilent Technologies announced a collaboration to enhance the development of companion diagnostic solutions powered with AI for precision medicine.

✅ Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
On July 2, 2025, Lunit and Microsoft announced a collaboration to advance AI-driven cancer diagnosis, aiming to improve diagnostic accuracy and patient outcomes.

Europe - Industry Developments:

✅ Warburg Pincus Acquires Stake in Sebia Diagnostics
On October 11, 2025, private equity firm Warburg Pincus acquired a significant minority stake in French diagnostics company Sebia, valuing the firm at €5.4 billion.

✅ Roche to Complete $1.5 Billion Acquisition of Poseida
On January 8, 2025, Roche announced plans to complete its acquisition of Poseida Therapeutics for approximately $1.5 billion, enhancing its development pipeline amid declining oncology sales.

Growth Forecast Projected:

The Global Cancer Diagnostic Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Cancer Diagnostic Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cancer-diagnostic-market?sg

Key Segments:

By Product Type (Consumables, Antibodies, Kits & Reagents, Probes, Others, Instruments, Pathology-based, Tissue Processing Systems, Cell Processors, PCR Instruments, Microarrays, Others, Imaging, CT Systems, Ultrasound Systems, MRI Systems, Mammography Systems, Others)

By Technology (IVD Testing, In Situ Hybridization (ISH), Next-generation Sequencing (NGS), Imaging, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Others)

By Cancer Type (Breast Cancer, Colorectal Cancer, Cervical Cancer, Lung Cancer, Others)

By End User (Hospitals and Clinics, Diagnostic Laboratories, Cancer Care and Research Institutes, Others)

By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Cancer Diagnostic producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Cancer Diagnostic revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cancer-diagnostic-market?sg

FAQ's

Q1: What is the current size of the Cancer Diagnostic Market?

A: The Cancer Diagnostic Market stood at US$ 21.71 billion in 2024 and is set to experience remarkable growth, reaching US$ 42.64 billion by 2033

Q2: How fast is the Cancer Diagnostic Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 8.7% from 2025-2033

Q3: Which regions are dominating the Cancer Diagnostic Market and which are fastest-growing?

A: North America is expected to hold a significant position in the global cancer diagnostics market, with the highest market share.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/cancer-diagnostic-market?sg

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.